IFRX Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
InflaRx N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.52 |
52 Week High | US$4.70 |
52 Week Low | US$1.14 |
Beta | 1.27 |
1 Month Change | 12.59% |
3 Month Change | 0.66% |
1 Year Change | -64.98% |
3 Year Change | -47.22% |
5 Year Change | -95.84% |
Change since IPO | -89.86% |
Recent News & Updates
Recent updates
We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Dec 23InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans
Aug 17We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Mar 28Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?
Nov 30InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients
Sep 29InflaRx reports Q2 results
Aug 05InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients
Jul 26Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation
Jul 16InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder
Jul 06InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy
Jun 29Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?
Apr 01Our First Look At InflaRx
Dec 29Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)
Dec 15InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans
Aug 27InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks
Aug 25InflaRx initiates mid-stage vilobelimab skin cancer trial
Jun 08We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth
May 01Do Institutions Own InflaRx N.V. (NASDAQ:IFRX) Shares?
Mar 02We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Jan 08InflaRx concludes enrollment in vilobelimab study in blood vessel inflammation disorder
Jan 05InflaRx reports Q3 results
Oct 29Shareholder Returns
IFRX | US Biotechs | US Market | |
---|---|---|---|
7D | 6.3% | 2.2% | 1.7% |
1Y | -65.0% | 5.8% | 26.0% |
Return vs Industry: IFRX underperformed the US Biotechs industry which returned 5.8% over the past year.
Return vs Market: IFRX underperformed the US Market which returned 26% over the past year.
Price Volatility
IFRX volatility | |
---|---|
IFRX Average Weekly Movement | 10.4% |
Biotechs Industry Average Movement | 11.1% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.1% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: IFRX has not had significant price volatility in the past 3 months.
Volatility Over Time: IFRX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 62 | Niels Riedemann | www.inflarx.de |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
InflaRx N.V. Fundamentals Summary
IFRX fundamental statistics | |
---|---|
Market cap | US$90.68m |
Earnings (TTM) | -US$44.77m |
Revenue (TTM) | US$107.61k |
831.8x
P/S Ratio-2.0x
P/E RatioIs IFRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IFRX income statement (TTM) | |
---|---|
Revenue | €99.13k |
Cost of Revenue | €752.78k |
Gross Profit | -€653.66k |
Other Expenses | €40.59m |
Earnings | -€41.24m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.70 |
Gross Margin | -659.42% |
Net Profit Margin | -41,604.56% |
Debt/Equity Ratio | 0% |
How did IFRX perform over the long term?
See historical performance and comparison